S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NYSE:SNN

Smith & Nephew - SNN Stock Forecast, Price & News

$27.14
-0.05 (-0.18%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.12
▼
$27.37
50-Day Range
$22.26
▼
$27.19
52-Week Range
$21.77
▼
$36.68
Volume
576,564 shs
Average Volume
960,966 shs
Market Capitalization
$11.81 billion
P/E Ratio
N/A
Dividend Yield
2.06%
Price Target
N/A

Smith & Nephew MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.78% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
8.28%
From $1.57 to $1.70 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

616th out of 1,034 stocks

Surgical Appliances & Supplies Industry

16th out of 23 stocks

See Top Rated MarketRank™ Stocks Here
SNN stock logo

About Smith & Nephew (NYSE:SNN) Stock

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Receive SNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SNN Stock News Headlines

November 5, 2022 | seekingalpha.com
Smith & Nephew plc (SNN) Q3 2022 Earnings Call Transcript
October 12, 2022 | finance.yahoo.com
Palm Valley Capital: “Smith & Nephew (SNN) is a High-Quality Business”
October 11, 2022 | finance.yahoo.com
10 Best International Stocks to Buy Now
September 26, 2022 | seekingalpha.com
Smith & Nephew: Still A Buy Despite Short-Term Challenges
September 16, 2022 | nasdaq.com
First Week of November 18th Options Trading For Smith & Nephew (SNN)
September 14, 2022 | finance.yahoo.com
Smith & Nephew's Implant Shows 86% Reduction In Re-Tear Rates After Shoulder Surgery
September 14, 2022 | finance.yahoo.com
New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months
August 9, 2022 | uk.finance.yahoo.com
Another day, another profits warning – but here's why you should stick by Smith & Nephew
August 5, 2022 | finance.yahoo.com
Is There An Opportunity With Smith & Nephew plc's (LON:SN.) 36% Undervaluation?
August 4, 2022 | finance.yahoo.com
Smith+Nephew's OXINIUM™ Technology Tour of Change touches down at the Pro Football Hall of Fame during enshrinement weekend
June 16, 2022 | msn.com
Political leaders clash over Smith & Nephew move to leave Hull
June 16, 2022 | bbc.com
Smith & Nephew: Hull Labour group asks government to step in
June 14, 2022 | finance.yahoo.com
SMITH+NEPHEW SHARES NEW RESEARCH THAT ESTIMATES 3.5 BILLION HOURS OF NURSE TIME COULD BE RELEASED BY 2030 THROUGH SHARED WOUND CARE AND USE OF LONG-WEAR ADVANCED FOAM DRESSINGS
June 9, 2022 | finanznachrichten.de
Smith & Nephew plc: Smith+Nephew announces new UK R&D and manufacturing facility for Advanced Wound Management with $100m+ investment near Hull
June 8, 2022 | finance.yahoo.com
Smith+Nephew announces first total hip replacement cases on its CORI™ Surgical System using RI.HIP MODELER and RI.HIP NAVIGATION
June 1, 2022 | seekingalpha.com
Smith & Nephew sells 2 wound-healing cell therapies to Healiva
June 1, 2022 | seekingalpha.com
Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier
April 28, 2022 | seekingalpha.com
Smith & Nephew reports Q1 results
April 4, 2022 | finance.yahoo.com
Should Weakness in Smith & Nephew plc's (LON:SN.) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
March 31, 2022 | finance.yahoo.com
Form 8.3 - SNN LN Equity 28-March-22 Dealing Disclosure (AMENDMENT)
March 29, 2022 | finance.yahoo.com
Form 8.3 - SNN LN Equity 28-March-22 Dealing Disclosure
March 28, 2022 | finance.yahoo.com
Form 8.3 - SNN LN Equity 25-March-22 Dealing Disclosure
March 17, 2022 | uk.finance.yahoo.com
Top investment tips for a stocks and shares ISA
March 4, 2022 | benzinga.com
Redburn Partners Upgrades Smith & Nephew to Neutral
February 26, 2022 | finance.yahoo.com
Smith & Nephew plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
See More Headlines
Receive SNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SNN Company Calendar

Last Earnings
11/17/2014
Ex-Dividend for 10/26 Dividend
9/29/2022
Dividend Payable
10/26/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:SNN
CUSIP
N/A
CIK
845982
Web
www.smith-nephew.com
Phone
441923477100
Fax
44-20-7930-3353
Employees
18,000
Year Founded
1856

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
17.29
P/E Growth
3.13
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.42
Current Ratio
1.78
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$5.21 billion
Price / Sales
2.27
Cash Flow
$2.93 per share
Price / Cash Flow
9.26
Book Value
$12.66 per share
Price / Book
2.14

Miscellaneous

Outstanding Shares
435,304,000
Free Float
430,951,000
Market Cap
$11.81 billion
Optionable
Optionable
Beta
0.61

Social Links


Key Executives

  • Ms. Anne-Francoise Nesmes (Age 50)
    CFO & Exec. Director
    Comp: $1.71M
  • Dr. Deepak S. Nath Ph.D. (Age 49)
    CEO & Director
  • Mr. Paul Connolly (Age 54)
    Pres of Global Operations
  • Mr. Andrew Swift
    VP of Investor Relations
  • Ms. Helen Barraclough (Age 43)
    Group Gen. Counsel, Company Sec. & Director
  • Ms. Alison Parkes (Age 50)
    Chief Compliance Officer
  • Mr. Joe Metzger
    Sr. VP of Marketing Services & Communications
  • Ms. Elga Lohler (Age 54)
    Chief HR Officer
  • Mr. Philip G. Cowdy (Age 55)
    Chief Bus. Devel. & Corp. Affairs Officer
  • Mr. Bradley Cannon (Age 54)
    Pres of Orthopaedics, Sports Medicine & ENT and Americas

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SNN Stock - Frequently Asked Questions

Should I buy or sell Smith & Nephew stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SNN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares.
View SNN analyst ratings or view top-rated stocks.

How have SNN shares performed in 2022?

Smith & Nephew's stock was trading at $34.62 at the beginning of 2022. Since then, SNN shares have decreased by 21.6% and is now trading at $27.14.
View the best growth stocks for 2022 here.

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) announced its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.59.

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew announced a semi-annual dividend on Monday, August 1st. Stockholders of record on Friday, September 30th will be given a dividend of $0.288 per share on Wednesday, October 26th. This represents a yield of 2.8%. The ex-dividend date is Thursday, September 29th.
Read our dividend analysis for SNN.

Is Smith & Nephew a good dividend stock?

Smith & Nephew (NYSE:SNN) pays an annual dividend of $0.56 per share and currently has a dividend yield of 2.06%.
Read our dividend analysis for SNN.

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fiduciary Management Inc. WI (1.61%), Scharf Investments LLC (0.47%), Raymond James & Associates (0.24%), Point72 Asset Management L.P. (0.10%), Dimensional Fund Advisors LP (0.08%) and Bank of Montreal Can (0.07%).

How do I buy shares of Smith & Nephew?

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Smith & Nephew's stock price today?

One share of SNN stock can currently be purchased for approximately $27.14.

How much money does Smith & Nephew make?

Smith & Nephew (NYSE:SNN) has a market capitalization of $11.81 billion and generates $5.21 billion in revenue each year.

How many employees does Smith & Nephew have?

The company employs 18,000 workers across the globe.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The official website for the company is www.smith-nephew.com. The medical equipment provider can be reached via phone at 441923477100, via email at andrew.swift@smith-nephew.com, or via fax at 44-20-7930-3353.

This page (NYSE:SNN) was last updated on 12/9/2022 by MarketBeat.com Staff